Abstract 551P
Background
The use of immune checkpoint inhibitors (ICI) has transformed the management of non-small cell lung cancer (NSCLC). With improved cancer outcomes have come increased auto-immune toxicities, which could affect any organ system. We investigated the incidence and outcomes of immune-related adverse events (irAE) in a large cohort of NSCLC patients.
Methods
Medical records from a metropolitan cancer centre in the AUstralian Registry and biObank of thoRAcic cancers (AURORA) registry were reviewed. Kaplan Meier analysis was used for survival estimates. Risk factors were tested using Fishers Exact test and logistic regression. False discovery rate of 5% was used to correct for multiple testing.
Results
Between 2013-2021, 449 patients received ICI. The median age was 65 years, 61% were male. Most (91%) had an ECOG of 0-1, 68% had metastatic disease at diagnosis, and 70% had adenocarcinoma. ICI was given as first line treatment in 47% of patients, and 22% had curative intent therapy. irAE were identified in 106 patients (24%). Most frequent was pneumonitis in 34 patients (incidence 7.6%); followed by colitis in 21 (4.5%), acute kidney injury in 19 (4.2%), thyroid disorders in 14 (3.1%), hepatitis in 12 (2.7%), skin toxicity in eight (1.8%), myositis in four (0.9%) and cardiac disorders and hypoadrenalism in three (0.7%) each. Toxicities noted twice included: arthropathy, hypoadrenalism, encephalitis, blood dyscrasias, diabetes, and ocular toxicities. Diabetes, gastritis and enteritis were identified in one patient each. Nineteen (4.2%) patients had two toxicities, one patient recorded three toxicities and one had four. No relationship was found between irAE and ICI combination therapy, smoking, age, performance status, or sex. The rate of pneumonitis was higher in those with airways disease than in those without (OR 14.81, 95% CI 6.64-33.59, P<0.01). Median overall survival in those with irAE was 18.7 months, versus 9.2 months in those without (HR 0.54, 95%CI 0.42-0.70, P=<0.01).
Conclusions
In a real word cohort, immune-related toxicities were similar to those reported in the literature. The development of irAE was associated with improved survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
B. Solomon: Financial Interests, Institutional, Advisory Board: AstraZeneca, Novartis, Merck, Bristol Myers Squibb; Financial Interests, Personal, Invited Speaker: Pfizer, AstraZeneca, Roche/Genentech; Financial Interests, Personal, Advisory Board: Amgen, Roche-Genentech, Eli Lilly, Takeda, Janssen; Financial Interests, Personal, Full or part-time Employment, Employed as a consultant Medical Oncologist at Peter MacCallum Cancer Centre: Peter MacCallum Cancer Centre; Financial Interests, Personal, Member of Board of Directors: Cancer Council of Victoria, Thoracic Oncology Group of Australasia; Financial Interests, Personal, Royalties: UpToDate; Financial Interests, Institutional, Steering Committee Member, Principal Investigator and Steering committee Chair: Roche/Genentech, Pfizer; Financial Interests, Institutional, Steering Committee Member: Novartis. M. Alexander: Financial Interests, Personal, Advisory Board: BMS/Pfizer. T. John: Financial Interests, Personal, Invited Speaker, Speaker tour Vietnam: AstraZeneca; Financial Interests, Personal, Invited Speaker, CTIO: Merck Sharp Dohme; Financial Interests, Personal, Advisory Board: BMS, AstraZeneca, Bayer, Specialised Therapeutics; Financial Interests, Institutional, Advisory Board: Roche, Novartis, Pfizer, Amgen, Takeda, PharmaMar; Financial Interests, Personal, Other, Speaker/Chair: ACE Oncology. All other authors have declared no conflicts of interest.
Resources from the same session
309P - Expression of estrogen receptor is a negative predictive biomarker for immunotherapy with lenvatinib plus pembrolizumab for advanced endometrial cancer with pMMR
Presenter: Hiroyuki Fujii
Session: Poster Display
Resources:
Abstract
310P - A study on the prediction of recurrence site of endometrial cancer using various machine learning techniques
Presenter: Wonkyo Shin
Session: Poster Display
Resources:
Abstract
311P - Circulating cytokines in the differential diagnosis of endometrial cancer
Presenter: Tatyana Abakumova
Session: Poster Display
Resources:
Abstract
312P - Molecular and genetic features of squamous cell carcinoma of vulvar cancer depending on HPV status
Presenter: Visola Navruzova
Session: Poster Display
Resources:
Abstract
313P - Efficacy and safety of oral metronomic chemotherapy in recurrent refractory advanced gynaecological cancer: Experience from regional cancer center of eastern India
Presenter: Ranti Ghosh
Session: Poster Display
Resources:
Abstract
314P - Perioperative outcomes in advanced epithelial ovarian cancer treated with neoadjuvant bevacizumab and chemotherapy: Real-world experience from an Indian cancer centre
Presenter: Upasana Palo
Session: Poster Display
Resources:
Abstract
315P - Real-world experience of niraparib as maintenance therapy in newly diagnosed advanced ovarian cancer: A single-center retrospective study
Presenter: Wenxin Liu
Session: Poster Display
Resources:
Abstract
316P - First evidence of olaparib maintenance therapy in patients with newly diagnosed BRCA wild-type ovarian cancer: A real-world multicenter study
Presenter: Jing Li
Session: Poster Display
Resources:
Abstract
317P - Attitudes of Israeli gynecologists towards risk reduction salpingo-oophorectomy at hysterectomy for benign conditions and the use of hormonal therapy
Presenter: wisam Assaf
Session: Poster Display
Resources:
Abstract
319P - Survival prediction for ovarian cancer patients from Taiwan cancer registry data
Presenter: Tzu-Pin Lu
Session: Poster Display
Resources:
Abstract